From FDA labels and ClinicalTrials.gov

Are GLP-1s studied in people with HIV?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists people with HIV as an approved use, so prescribing one for it would be off-label. Randomized trial, NIH funded (Semaglutide): In HIV-associated lipohypertrophy, abdominal visceral fat fell 30.6% over 32 weeks against placebo. The authors want larger trials to check serious side effects. Lancet Diabetes Endocrinol, 2024 (pubmed.ncbi.nlm.nih.gov/38964353). ClinicalTrials.gov lists 12 trials of these medicines on it: 3 with posted results and 4 recruiting now.

Read from the registry and PubMed every day. The newest update here is Oct 27, 2026.

Published results

What the largest trials on people with HIV found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Randomized trial, NIH funded

Semaglutide · 108 people · Better than the comparison · Placebo-controlled randomized trial

In HIV-associated lipohypertrophy, abdominal visceral fat fell 30.6% over 32 weeks against placebo. The authors want larger trials to check serious side effects.

Lancet Diabetes Endocrinol, 2024 (pubmed.ncbi.nlm.nih.gov/38964353)

The registry

Trials on people with HIV, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide724
Liraglutide200
Tirzepatide200
Exenatide110
Posted results

What trials on people with HIV reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT01791465Pilot Study of Bydureon to Treat Diabetes in HIV-infected AdultsExenatidePhase 46On ClinicalTrials.gov (clinicaltrials.gov)
NCT04019197Effects of Semaglutide in HIV-Associated LipohypertrophySemaglutidePhase 2108Effects of Semaglutide on Quantity of Ectopic Fat (Total Pericardial Fat) at Week 32 Compared to Baseline (mL), 32 weeks. Semaglutide: -1.85; Placebo: 0.00.
NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)SemaglutidePhase 251On ClinicalTrials.gov (clinicaltrials.gov)
Recruiting now

Trials on people with HIV taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV (clinicaltrials.gov/study/NCT07221214)SemaglutidePhase 2Jan 31, 2030
Incretin Microdosing for Cardiometabolic Health in People With HIV (clinicaltrials.gov/study/NCT07325500)SemaglutidePhase 2Jun 30, 2029
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide (clinicaltrials.gov/study/NCT07040592)SemaglutidePhase 2Jun 30, 2027
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV (clinicaltrials.gov/study/NCT04174755)SemaglutideNot phasedJul 2027
From PubMed

Newest papers on GLP-1s and people with HIV

  • Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial (pubmed.ncbi.nlm.nih.gov/42921178)

    Randomized trial · Open Forum Infect Dis · Oct 5, 2026 · Adekunle RO et al.

  • Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy (pubmed.ncbi.nlm.nih.gov/42156721)

    Randomized trial · Nat Commun · May 19, 2026 · Corley MJ et al. · cited by 9

  • Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial (pubmed.ncbi.nlm.nih.gov/41098140)

    Randomized trial · Clin Infect Dis · May 1, 2026 · Atieh O et al. · cited by 6

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

GLP-1s and people with HIV: common questions

What did the largest trial on people with HIV find?

Randomized trial, NIH funded (Semaglutide, 108 people): In HIV-associated lipohypertrophy, abdominal visceral fat fell 30.6% over 32 weeks against placebo. The authors want larger trials to check serious side effects.

Is any GLP-1 FDA approved for people with HIV?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for people with HIV?

Semaglutide, with 7 registered trials on it, then Liraglutide and Tirzepatide with 2 each. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for people with HIV?

4 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.